Patents by Inventor Fenglei Zhang

Fenglei Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20190211014
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 19, 2018
    Publication date: July 11, 2019
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
    Publication number: 20190209537
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 11, 2019
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10300051
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 28, 2019
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20190144439
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: June 12, 2018
    Publication date: May 16, 2019
    Inventors: Liangxing Wu, Bo Shen, Jingwei Li, Zhenwu Li, Kai Liu, Fenglei Zhang, Wenqing Yao
  • Aza spiro alkane derivatives as inhibitors of metalloproteases
    Patent number: 10226459
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 12, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20190062301
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 28, 2019
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Bo Shen, Wenqing Yao, Fenglei Zhang
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20190062345
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 28, 2019
    Inventors: Kaijiong Xiao, Fenglei Zhang, Liangxing Wu, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20190062327
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: July 2, 2018
    Publication date: February 28, 2019
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
  • HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
    Publication number: 20190055250
    Abstract: The present invention is directed to compounds of Formula I which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: March 7, 2018
    Publication date: February 21, 2019
    Inventors: Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20190040082
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 7, 2019
    Inventors: Kaijiong Xiao, Fenglei Zhang, Liangxing Wu, Wenqing Yao
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10174030
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: January 8, 2019
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Xiaozhao Wang, Joel R. Courter, Fenglei Zhang, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20180273519
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 27, 2018
    Inventors: Liangxing Wu, Zhiyong Yu, Fenglei Zhang, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10040790
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: August 7, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Chunhong He, Fenglei Zhang
  • THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
    Publication number: 20180193323
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Application
    Filed: November 16, 2017
    Publication date: July 12, 2018
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20180179197
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20180179179
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Liangxing Wu, Zhiyong Yu, Fenglei Zhang, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20180177784
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Liangxing Wu, Ding-Quan Qian, Liang Lu, Neil Lajkiewicz, Leah C. Konkol, Zhenwu Li, Fenglei Zhang, Jingwei Li, Haisheng Wang, Meizhong Xu, Kaijiong Xiao, Wenqing Yao
  • AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases
    Publication number: 20180153882
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Application
    Filed: September 29, 2017
    Publication date: June 7, 2018
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • Heterocyclic compounds as LSD1 inhibitors
    Patent number: 9944647
    Abstract: The present invention is directed to compounds of Formula I which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 17, 2018
    Assignee: Incyte Corporation
    Inventors: Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20180057486
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 28, 2017
    Publication date: March 1, 2018
    Inventors: Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao